Amendments

In the Specification:

Please amend the specification as follows.

Please delete the paragraph on page 5, line 22 and continuing to page 6, line 9 and substitute the following therefor:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 1;

p is 0;

R^1 is H, CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl, 4-pyridylmethyl or 3-pyridylmethyl; provided that if R^1 is 3-pyridylmethyl or 4-pyridylmethyl, then X is CH_2, n is 1, Y is CH_2, m is 0 or 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together is oxygen;

R^2 is phenyl, 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 is $CH_2CH_2N(CH_2CH_3)_2$, then X is CH_2, n is 1, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together represent O;

R^5 and R^6 together are O or S; or

pharmaceutically acceptable salts and solvates thereof.

Please delete the paragraph beginning on page 6, line 25 and continuing to page 7, line 9 and substitute the following therefor:

W is H;

X is CH_2 or NH; n is 1;

Y is CH_2; m is 0 or 1, provided that if X is CH_2 and m is 0, then R^1 is not CH_2CH_3;

p is 0;

R^1 is CH_3, CH_2CH_3, $(CH_2)_2CH_3$, $(CH_2)_3CH_3$, $[CH_2(CH_3)_2]$ $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $C(CH_3)_3$, benzyl or 4-pyridylmethyl; provided that when R^1 is 4-pyridylmethyl, then X is CH_2, Y is CH_2, m is 1, R^2 is 2-fluorophenyl, R^3 is Cl, R^4 is H and R^5 and R^6 together represent oxygen;

R^2 is 2-fluorophenyl, 2-chlorophenyl or 2-pyridyl,

R^3 is Cl, Br or NO_2;

R^4 is H, CH_3 or $CH_2CH_2N(CH_2CH_3)_2$; provided that when R^4 is $CH_2CH_2N(CH_2CH_3)_2$, then X is CH_2, Y is CH_2, m is 1, R^1 is CH_3 or benzyl, R^2 is 2-fluorophenyl, R^3 is Cl and R^5 and R^6 together represent O;

R^5 and R^6 together represent O or S; or

pharmaceutically acceptable salts and solvates thereof.

Please delete the paragraph on page 3, lines 5-25 and substitute the following therefor:

wherein

W is H or C_1-C_4 branched alkyl or a straight chained alkyl;

X is CH_2, NH, or NCH_3; n is 1 or 2;

Y is O, CH_2; m is 0 or 1, provided that if X is CH_2, n is 1 and m is 0, then R^1 is not CH_2CH_3;

Z is O; p is 0 or 1;

R^1 is H, a C_1-C_7 straight chain alkyl, a C_3-C_7 branched chain alkyl, a C_1-C_4 haloalkyl, a C_3-C_7 cycloalkyl, an aryl, a heteroaryl, an aralkyl, or a heteroaralkyl;

R^2 is phenyl, 2-halophenyl or 2-pyridyl,

R^3 is H, Cl, Br, F, I, CF_3 or NO_2;

(1) R^4 is H, C_1-C_4 alkyl, or dialkylaminoalkyl and R^5 and R^6 together represent a single oxygen or S atom which is linked to the diazepine ring by a double bond and p is zero or 1 (as depicted in formula Ia); or (2) R^4 and R^5 together form a double bond in the diazepine ring and R^6 represents the group NHR^7 wherein R^7 is H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, ~~pyridylC_{1-2}alkyl, imidazolylC_{1-2}alkyl~~, 4-pyridylmethyl, 4-pyridylethyl, 4-imidazolylethyl, benzyl or benzyl mono or disubstituted independently with halogen substituents, C_{1-4}alkylpyridyl or C_{1-4} alkylimidazolyl and p is zero (as depicted in formula Ib);

or (3) R^4, and R^6 form the group $-CR^8=U-V=$ wherein R^8 is hydrogen, C_{1-4} alkyl, or C_{1-3} hydroxyalkyl, U is N or CR^9 wherein R^9 is H, C_{1-4}alkyl, C_{1-3}hydroxyalkyl or C_{1-4}alkoxy- C_{1-4}alkyl, V is N or CH and p is zero (as depicted in formula Ic);

or pharmaceutically acceptable salts and or solvates thereof.